Quantcast

Industry news that matters to you.  Learn more

PROOF Centre Collaboration Focuses on Prognostic Biomarkers for Chronic Kidney Disease

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) recently announced a new partnership with AstraZeneca and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) to develop a blood test to predict the rate of disease progression in patients with chronic kidney disease (CKD).

Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the launch of the CLIA-validated androgen receptor expression assay using a patient’s blood for the detection and monitoring of late-stage prostate cancer and a certain form of breast cancer.

Biodesix’ GeneStrat Blood-Based Mutation Test Now Includes EML4-ALK Fusions

Biodesix, Inc. recently announced that the GeneStrat™ blood-based panel now includes EML4-ALK fusions in addition to EGFR sensitizing, EGFR T790M, KRAS, and BRAF mutations. GeneStrat is a non-invasive, blood-based test analyzing circulating tumor DNA and RNA, designed to provide fast, accurate results in 72 hours for newly diagnosed non-small cell lung cancer (NSCLC) patients.

Banyan Biomarkers Reports Successful Clinical Trial Results of Blood Test to Evaluate Mild and Moderate Traumatic Brain Injury

Banyan Biomarkers, Inc., the leader in developing biomarkers for traumatic brain injury (TBI), today announced the results of a clinical study utilizing a blood test to evaluate mild and moderate TBI. The results, published online in the Journal of Neurotrauma, indicate that the two highly brain specific biomarkers in Banyan Biomarkers’ blood test, ubiquitin c-terminal hydrolase-L 1 (UCH-L1) and glial fibrillary acidic protein (GFAP), are detectable in blood shortly after a TBI. The test was able to identify 100% of the trial subjects who went on to have a positive computed tomography (CT) scan of the head. The results demonstrate that early biomarker testing for patients with mild to moderate TBI has the potential to provide clinicians with objective evidence needed to reduce CT use that is associated with increased healthcare costs and developing cancer over the long term.

Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)

Biodesix, Inc., recently announced that its data on genomic and proteomic blood-based diagnostic assays will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. These blood-based diagnostic tests for patients with non-small cell lung cancer (NSCLC) are developed with a focus on results within 72 hours of the patient’s blood being drawn so that clinicians can make treatment decisions sooner. The data will be presented as three posters.